The Food and Drug Administration (FDA) questioned the validity of an experimental drug for the treatment of chronic obstructive pulmonary disease (COPD), cautioning its panel of advisors that the data is incomplete and may not give a clear picture of efficacy and potential adverse reactions. The treatment, called Anoro Ellipta, is a combination of two drugs, umeclidinium and vilanterol, neither of which has been approved by the FDA as a single therapy. Anoro Ellipta is manufactured by GlaxoSmithKline and Theravance Inc. The two companies in May had secured FDA approval for another COPD drug, Breo Ellipta, and had hoped to keep ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.